A fundamentally new approach for the treatment of Alzheimer’s and Parkinson’s disease
Alzheimer’s and Parkinson’s disease result from a loss of neuronal function.
GraySpace Therapeutics has the solution.
Our mission is the development of a novel therapy that restores, and prevents, the age-related onset of neuronal degeneration that is intimately linked to memory and cognition. Our therapy also is neuroprotective and prevents the onset of Levodopa-induced dyskinesia (LID) in Parkinson’s disease.
PPI-1011: Plasmalogen Augmentation Supercharged
PPI-1011 is a first-in-class, highly potent and orally bioavailable ether lipid membrane modifier intended for the treatment of Alzheimer’s disease and related dementias. It has also been shown in Parkinson’s disease to be neuroprotective and prevent Levodopa-induced dyskinesia. PPI-1011 increases plasmalogen levels in the body, which is designed to improve memory and neurological function through increased neurotransmitter release and re-uptake, neurotransmitter receptor clustering, and activity of membrane-bound proteins such as the secretases involved in beta amyloid production.
The recent failure of multiple amyloid-targeted therapies means we must look to new approaches for treating Alzheimer’s disease… plasmalogen replacement could be that approach
Latest News!
Be Part of the Solution
Join our fight against Alzheimer’s and Parkinson’s disease by investing, advising, or working with our world-class team!